Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY dexamethasone
 
NCT04381936
RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif
  • demonstrated 17 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 10 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
  • suggested 23 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
in an exploratory subgroup analysis there was no benefit among patients who did not require oxygen (1.22 [0.86 to 1.75]; p=0.14)

COVID-19 severe or critically meta-analysis

COVID STEROID 2
 
NCT04509973
RCTDexamethasone 12mgdexamethasone 6mgCOVID-19 severe or criticallylow
497/485 inconclusive
    Jamaati
     
    IRCT20151227025726N1
    RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    25/25 suggested
    • inconclusive 19 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 38 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 3.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    CODEX (Tomazini)
     
    NCT04327401
    RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
    151/148 inconclusive
      DEXA-COVID19
       
      NCT04325061
      RCTdexamethasonestandard of careCOVID-19 severe or criticallylow
      7/12 inconclusive
        1 study excluded by filtering options (1 RCT / 0 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).